Megan Minch, MD
Endocrinology, Diabetes & Metabolism · Lexington, KYNPI 1356756720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 218 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,161 and has fallen 76.7% since, to $271 in 2025.
Across 218 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$552
- Boehringer Ingelheim$469
- Novo Nordisk$464
- Medtronic$315
- AstraZeneca$313
- AbbVie$277
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,134100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 14 | $552 |
| Boehringer Ingelheim | 33 | $469 |
| Novo Nordisk | 28 | $464 |
| Medtronic(2 entities) | 7 | $315 |
| AstraZeneca | 22 | $313 |
| AbbVie | 18 | $277 |
| Abbott | 13 | $215 |
| Sanofi-aventis U.S. LLC | 12 | $202 |
| Lilly USA, LLC | 13 | $200 |
| Amarin Pharma, Inc. | 9 | $152 |
| Mannkind Corporation | 9 | $150 |
| Biotissue Holdings Inc. | 1 | $146 |
| Antares Pharma, Inc. | 4 | $111 |
| Amgen(2 entities) | 7 | $106 |
| Corcept Therapeutics | 5 | $86 |
| Bayer | 4 | $63 |
| Vistapharm, Inc. | 4 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $57 |
| Radius Health, Inc. | 3 | $49 |
| BETA Bionics, Inc. | 1 | $39 |
| Zealand Pharma US, Inc. | 2 | $30 |
| Almatica Pharma LLC | 1 | $26 |
| Amryt Pharma Holdings Ltd | 1 | $17 |
| IBSA Pharma Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$113
- Ozempic$109
How this compares
$4,146 in reported general payments places this provider in the 55th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
See all endocrinology, diabetes & metabolism providers in Kentucky →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 184 | $258,048 |
| MounjaroTirzepatide | 144 | $174,384 |
| JardianceEmpagliflozin | 143 | $137,203 |
| TrulicityDulaglutide | 77 | $130,454 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $62,784 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $59,767 |
| FarxigaDapagliflozin Propanediol | 71 | $59,476 |
| Tresiba Flextouch U-200Insulin Degludec | 42 | $49,954 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 83 | $46,717 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 61 | $46,542 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 256 | $37,769 |
| JanuviaSitagliptin Phosphate | 27 | $33,237 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $30,455 |
| RybelsusSemaglutide | 20 | $23,715 |
| Novolog FlexpenInsulin Aspart | 85 | $23,631 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $200 | $306,282235 claims |
| Novo NordiskOzempic, Rybelsus | $464 | $281,763204 claims |
| Boehringer IngelheimJardiance | $469 | $137,203143 claims |
| AstraZenecaFarxiga | $313 | $59,47671 claims |
| MerckJanuvia, Janumet | $12 | $48,46843 claims |
| AbbVieSynthroid | $277 | $4,79558 claims |
| Sanofi-aventis U.S. LLCLantus | $202 | $3,60819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 90 endocrinology, diabetes & metabolism providers in Kentucky.
Other endocrinology, diabetes & metabolism in Lexington
- Lyle MyersLexington$60K
- Wendell MiersLexington$38K
- Leera PatelLexington$34K
- Simon FisherLexington$26K
- Anna MarinoLexington$23K
- Gordon GuthrieLexington$14K
- Kenneth AinLexington$5K
- Walaa AyoubLexington$3K
- Kristina HumphriesLexington$3K
- Dennis KarounosLexington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.